Clinical Trial Update: FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC [Phase 2]

View source ↗

Summary

Phase 2 trial comparing FOLFOXIRI + cetuximab versus FOLFOXIRI + bevacizumab in first-line treatment of BRAF-mutated metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Cetuximab (cetuximab)
• FOLFOXIRI (folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin, irinotecan)

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN